J&J’s Psoriasis Blockbuster Shows Promise Against Lupus

Nov 06, 2017

Reuters

Johnson & Johnson’s blockbuster psoriasis drug, Stelara, showed promising results in a midstage clinical trial of patients with systemic lupus.

Janssen Biotech already has FDA approval for Sterlara for psoriasis (2009), psoriatic arthritis (2013) and Crohn’s disease (2016).

In the current trial of 102 patients with active lupus on standard therapy, 60 percent of those who received Stelara experienced improvement after 24 weeks of treatment. According to J&J, these results are strong enough to advance Stelara into larger Phase III testing.

Read the Reuters coverage 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments